LOW-VOLUME · FEMALE-LED
tiagabine Side Effects
tiagabine (also sold as Gabitril) is a LOW-VOLUME FAERS extract #520 of 524 by FAERS report count. Still opens on FEMALE-LED: 76% of sex-coded reports are female (55 F / 17 M).
Data updated 2026-05-15
- 81
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
tiagabine reporting skew - 76% of sex-coded reports are female (55 F / 17 M). Volume band LOW-VOLUME #520 of 524 by FAERS report count; caseload TRACE-CASE.
Thinner FAERS extract for tiagabine (Gabitril) (81 reports #520 of 524 by FAERS report count). 76% of sex-coded reports are female (55 F / 17 M). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2004–2025). Stamps TRACE-CASE · DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED.
ENCEPHALOPATHY leads 16 of 81 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (76% of sex-coded rows)
Age peak 45-64 (26 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (7 reports, 8.6%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 3 |
| DEATH | 2 |
| CARDIAC ARREST | 1 |
| CONVULSION | 1 |
| OVERDOSE | 1 |
| RESPIRATORY ARREST | 1 |
| UNEVALUABLE EVENT | 1 |
| WEIGHT INCREASED | 1 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (32, 39.5% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| ENCEPHALOPATHY | 14 |
| MYOCLONUS | 14 |
| FATIGUE | 3 |
| INSOMNIA | 3 |
| TOXICITY TO VARIOUS AGENTS | 3 |
| ANXIETY | 2 |
| DRUG INTERACTION | 2 |
| DYSARTHRIA | 2 |
| DYSKINESIA | 2 |
| HAEMOGLOBIN DECREASED | 2 |
| MUSCLE TWITCHING | 2 |
| PNEUMONIA | 2 |
| SEDATION | 2 |
| SOMNOLENCE | 2 |
| STATUS EPILEPTICUS | 2 |
| TREMOR | 2 |
| ABDOMINAL INJURY | 1 |
| ABDOMINAL PAIN | 1 |
How to read tiagabine FAERS figures (TRACE-CASE · DEATH-HEAVY · HOSP-HEAVY)
FAERS holds 81 voluntary reports linked to tiagabine (Gabitril), 2004-2025. Death is listed on 7 (8.6%). Hospitalization appears on 32 (39.5%). Top co-reported indication: Multiple Sclerosis.
Sparse extract - named reactions and FEMALE-LED skew still differ by drug; not a complete safety profile.
Read with tiagabine
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.
ABS(total_reports) peer at 73 FAERS cases (Δ 8 lighter vs tiagabine); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's TRACE-CASE · DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED.
ABS(total_reports) peer at 67 FAERS cases (Δ 14 lighter vs tiagabine); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's TRACE-CASE · DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED.
ABS(total_reports) peer at 96 FAERS cases (Δ 15 heavier vs tiagabine); DEATH-RARE · HOSP-MID · SEX-BALANCED vs this page's TRACE-CASE · DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED.
ABS(total_reports) peer at 108 FAERS cases (Δ 27 heavier vs tiagabine); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's TRACE-CASE · DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 53.5 pp vs tiagabine's DEATH-HEAVY): CASELOAD · HOSP-MID.
tiagabine stamps DEATH-HEAVY · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload TRACE-CASE and the label guide.